Orthofuse, a 3D-printed orthopaedic medtech company, has raised £2.2 million in a seed round led by a group of angel investors, with participation from ACF Investors, Cambridge Angels, and Empirical Ventures. It is developing implant systems designed to improve how complex orthopaedic procedures are performed. The funding will support technical development, regulatory readiness, and partnerships ahead of early-stage clinical evaluations.
Orthopaedic trauma and spinal degenerative conditions are technically demanding, time-sensitive, and challenging when bone quality is poor. Existing implant systems struggle to meet the needs of both patients and surgeons, often leading to prolonged surgical times and increased risks. Orthofuse is developing 3D-printed implant systems using advanced additive manufacturing techniques to reduce the number of steps required during insertion while maintaining strong fixation. Its designs also focus on reversibility, allowing surgeons to adjust or reposition hardware without compromising surrounding tissue.
The approach aims to simplify implant placement and reduce dependency on multi-step instrumentation, with the goal of shortening procedures, lowering complication risks, and improving patient recovery. In the next 12 months, Orthofuse plans to develop an implant system with support from leading surgeons in the US as it prepares for early-stage clinical evaluations.
The main pain point here is that orthopaedic trauma and spinal degenerative conditions are technically demanding, time-sensitive, and extremely challenging when there is poor bone quality. Current implant systems struggle to comprehensively meet the needs of the patient and the surgeon. The inherent limitations cause prolonged surgical times and increased risks to the patient. Modern surgical practice demands implant systems that reflect the realities of the operating room. Orthofuse is developing a technology designed to simplify procedures, giving surgeons greater flexibility and confidence. This investment enables us to accelerate progress toward setting a new standard for safety and efficiency in orthopaedic care.
Orthofuse has reimagined the fundamental architecture of implants to solve the inefficiencies of current solutions. We believe this approach has real value in improving orthopaedic care, and are pleased to support the team as they move forward.
Orthofuse is tackling a critical challenge in surgery by coupling advanced engineering and clinical practicality. James and his team have developed a truly innovative approach to implant architecture that has the potential to significantly improve patient outcomes whilst enhancing surgical efficiency, and we are delighted to support them in this journey.
